Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- ClinicalTrials.gov
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
clinical trialBiotech
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver (NCT03472586)
Source-permitted summary
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | Phase: PHASE2 | Conditions: Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
SourceClinicalTrials.govAI Reading Notes
Core signal
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
- Core signal
- Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | Phase: PHASE2 | Conditions: Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
- Field context
- Protein and Drug Design
- People and labs
- Not stated in the reviewed source.
- Why it matters
- Clinical trial registry updates are translation signals, not commercialization claims by themselves.
- Limits to check
- ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
Research Workflow
Research Workflow
Recommended next steps for turning this signal into research action.
- Read original source
- Check DOI/OpenAlex
- Open relationship graph
- Review people and labs: Not stated in the reviewed source.
- Open linked event for AISci context
- Prepare journal-club PPT: AISci action coming next
- Plan replication checks: AISci action coming next
Publication facts
- Type
- clinical trialSourceClinicalTrials.gov
- Date
- Jul 7, 2026SourceClinicalTrials.gov
- Venue
- ClinicalTrials.govSourceClinicalTrials.gov
- Open access
- openSourceClinicalTrials.gov
External IDs
Author order
No reviewed author edge is attached to this output.
Organizations
No source-confirmed author affiliation is attached.
Related events
Topics
Relationship evidence
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Organization linked by public source evidence.
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Clinical/translation signal: Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Timeline
- clinical trialIpilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver